Liquidia Q3 Sales Hit $222.7M as UTHR Settlement Lifts Loss

Liquidia Corporation (NASDAQ: LQDA) reported third-quarter 2026 net product sales of $222.7 million for YUTREPIA (treprostinil) inhalation powder, up 31% from the second quarter, alongside a $236.3 million net loss driven by a $389.7 million litigation settlement charge. The company announced the results on November 10, 2026, and said cash and cash equivalents reached $396.1 million at September 30, before settlement payments. Adjusted EBITDA was $140.5 million, the fifth consecutive quarterly increase.

Context — Why Liquidia's Settlement and Sales Both Matter Now

The quarter captures two opposing forces at once. YUTREPIA's commercial trajectory continues to steepen five quarters after launch, while a global settlement with United Therapeutics Corporation closed out all six pending lawsuits between the companies.

The settlement followed a September 30, 2026 ruling by the U.S. District Court for the District of Delaware that certain claims of U.S. Patent No. 11,826,327 — covering the treatment of pulmonary hypertension associated with interstitial lung disease, or PH-ILD, with inhaled treprostinil — were valid and infringed.

Under the agreement, Liquidia said it will not appeal, has submitted a Prior Approval Supplement to remove the PH-ILD indication from YUTREPIA's label, and has stopped promoting the drug for that use. YUTREPIA remains available without disruption and no patients are required to discontinue, the company said.

The company said it will pay a net $380.7 million in installments across 2026 and 2027, including payments to parties in antitrust litigation against United Therapeutics tied to Treprostinil Injection. Liquidia said it expects to fund the payments from existing cash and ongoing YUTREPIA sales.

That framing matters because the headline loss is an accounting event, not an operating one. Excluding the settlement charge, YUTREPIA sales alone pushed adjusted EBITDA to $140.5 million for the quarter — the fifth straight sequential increase — which is the operating signal the company is asking investors to weigh against the one-time legal hit.

Data — What the Numbers Show

Third-quarter product sales, net were $222.7 million, compared with $51.7 million in the same quarter of 2025 — a $171.0 million increase the company attributed to higher YUTREPIA volume. Liquidia began shipping YUTREPIA in the U.S. in June 2025 after full FDA approval in May 2025.

Metric	Q3 2026	Q3 2025
Product sales, net	$222.7M	$51.7M
Cost of product sales	$14.0M	$2.3M
R&D expense	$25.3M	$9.3M
SG&A expense	$59.0M	$40.1M
Net loss	$236.3M	$3.5M

The company reported $212.2 million in paid patient demand in the quarter, excluding voucher and patient access programs. Conversion of monthly referrals to patient starts stayed above 87%. The prescriber base reached 1,300 through October, with more first-time prescribers added in October than in September.

On the cost side, R&D rose 170% to $25.3 million, driven by an $11.1 million increase for the L606 program, $3.2 million for YUTREPIA R&D, and $1.2 million in personnel. SG&A rose 47% to $59.0 million on higher headcount, stock-based compensation, and commercial and consulting spend.

Cash and cash equivalents stood at $396.1 million versus $190.7 million at December 31, 2025. Total liabilities were $708.4 million, and total stockholders' equity swung to a $25.4 million deficit. An income tax benefit of $30.1 million partly offset the loss.

Analysis — What It Means for Healthcare and Biotech Tickers

The read-through for the inhaled prostacyclin space is that Liquidia has traded legal risk for a fixed cash obligation. The $389.7 million charge comprises $330.4 million payable to United Therapeutics, less a $10.0 million receivable, plus $60.3 million payable to antitrust parties and non-cash write-offs tied to the Sandoz Promotion Agreement, which was terminated in October 2026.

With PH-ILD removed from the label, YUTREPIA's addressable market narrows to PAH, where the company said more than 60% of referrals since launch included a PAH diagnosis, rising above 70% in September. That mix shift is the key variable for whether the sales trajectory holds.

A counter-argument worth weighing: the company's own pipeline carries execution risk. L606's Re-Spire pivotal study is not expected to complete enrollment until 2028 and primary completion until 2029, leaving a long gap before a second commercial asset arrives. The RE-WARM Phase 2 study in SSc-RP is faster — primary completion anticipated in 1Q2027 — but SSc-RP has no approved treatments and is a smaller market.

Positioning-wise, the equity now trades on operating EBITDA and cash runway rather than litigation outcomes. The $380.7 million net payment schedule is the dominant cash-flow item through 2027, and the company's ability to fund it from operations is the swing factor for holders.

Outlook — What to Watch Next

Three catalysts sit on the near-term calendar. First, the LTI-403 open-label study in PAH patients switching from oral selexipag has primary completion anticipated in 2Q2027. Second, the SPRINT hemodynamic trial is expected to initiate in 4Q2026. Third, the RE-WARM study's primary completion is anticipated in 1Q2027.

On the commercial side, October 2026 total patient shipments reached their highest monthly level since launch, though the daily referral rate in October was more than 75% of the third-quarter daily average — a deceleration the company disclosed. Whether that ratio stabilizes or slips is the single most useful near-term demand gauge.

Cash is the other watch item. The company ended the quarter with $396.1 million before settlement payments, and the first installments fall in 2026 and 2027. Investors will want to see the balance sheet absorb those payments while adjusted EBITDA keeps climbing.

Frequently Asked Questions

What does the United Therapeutics settlement mean for Liquidia shareholders?

It removes all six pending lawsuits and secures YUTREPIA's continued commercial availability, but it costs a net $380.7 million payable across 2026 and 2027 and strips the PH-ILD indication from the label. The company also agreed not to appeal the September 30, 2026 Delaware ruling and has ceased promoting YUTREPIA for PH-ILD. Shareholders now weigh a fixed cash obligation against a PAH-focused commercial ramp.

Why did Liquidia's net loss jump to $236.3 million in Q3 2026?

The loss reflects a $389.7 million litigation settlement charge recorded in the quarter, comprising amounts payable to United Therapeutics, payments to antitrust parties, and non-cash write-offs from the terminated Sandoz Promotion Agreement. Excluding that charge, YUTREPIA sales produced $140.5 million in non-GAAP adjusted EBITDA, the company's fifth consecutive quarterly increase. An income tax benefit of $30.1 million also reduced the reported loss.

How large is Liquidia's cash position after the settlement?

Cash and cash equivalents totaled $396.1 million as of September 30, 2026, up from $190.7 million at December 31, 2025 — but that figure predates the settlement payments. The company said it expects to fund the net $380.7 million obligation from current cash and ongoing YUTREPIA sales. Total liabilities rose to $708.4 million and stockholders' equity turned to a $25.4 million deficit.

Bottom Line

Liquidia bought legal certainty and a clean PAH label with a $389.7 million charge that masks a fifth straight quarter of rising operating EBITDA.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.